Eupatilin attenuates diabetic nephropathy by upregulating matrix metalloproteinase-9 expression in diabetic rat kidney
| Autor: | Guoliang Shi, Yali Xu, Gang Lin, Jing Yang, Wuzhou Zhang, Linxin Xu |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Creatinine
medicine.medical_specialty Kidney business.industry Eupatilin Pharmaceutical Science Glomerulosclerosis medicine.disease Streptozotocin Diabetic nephropathy chemistry.chemical_compound Endocrinology medicine.anatomical_structure chemistry Diabetes mellitus Internal medicine Eupatilin Streptozotocin Diabetic nephropathy MMP-9 Medicine Pharmacology (medical) Histopathology business medicine.drug |
| Zdroj: | Tropical Journal of Pharmaceutical Research; Vol 17, No 6 (2018); 1055-1060 |
| ISSN: | 1596-9827 1596-5996 |
| Popis: | Purpose: To evaluate the nephro-protective effect of eupatilin in diabetic nephropathic (DN) rats.Method: Diabetes was induced by intraperitoneal administration of streptozotocin (STZ, 55 mg/kg) and confirmed by fasting blood glucose results, while DN was determined by measuring serum urea and creatinine levels on day 40 after STZ administration. The eupatilin-treated group received eupatilin at 50 and 100 mg/kg, p.o. for 20 days, after which blood levels of some biochemical parameters, glomerulosclerosis index, eosinophilic cast index, and expression of MMP-9 were determined using standard procedures.Results: Treatment with eupatilin significantly decreased serum levels of glucose, creatinine and urea, and increased creatinine clearance, compared to the negative control group. Moreover, eupatilin attenuated changes in kidney histopathology, and significantly enhanced the expression of MMP-9 in the kidney tissues of the DN rats, relative to negative control group.Conclusion: These results indicate that eupatilin attenuates renal failure in STZ-induced DN rats by upregulating the expression of MMP-9.Keywords: Eupatilin, Streptozotocin, Diabetic nephropathy, MMP-9 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|